Last reviewed · How we verify
Standard continuous antiretroviral therapy
Standard continuous antiretroviral therapy, marketed by Hospital Clinic of Barcelona, holds a position in the antiretroviral market with a key composition patent expiring in 2028. The therapy's key strength lies in its established market presence and ongoing use for primary indications. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Standard continuous antiretroviral therapy |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid, HIV and Immune System (PHASE4)
- Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India (NA)
- The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV (NA)
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) (PHASE2)
- Differentiated Service Delivery for Pregnant and Postpartum Women Living With HIV and Their Infants (NA)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants
- Baricitinib Curative Repression of HIV-1 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: